Home » Stocks » BCLI

Brainstorm Cell Therapeutics Inc. (BCLI)

Stock Price: $5.46 USD 0.02 (0.37%)
Updated December 3, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 172.36M
Revenue (ttm) n/a
Net Income (ttm) -27.69M
Shares Out 31.15M
EPS (ttm) -1.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $5.46
Previous Close $5.44
Change ($) 0.02
Change (%) 0.37%
Day's Open 5.43
Day's Range 5.05 - 5.49
Day's Volume 829,535
52-Week Range 3.69 - 17.73

More Stats

Market Cap 172.36M
Enterprise Value 145.05M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 31.15M
Float n/a
EPS (basic) -1.05
EPS (diluted) -1.02
FCF / Share -1.01
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6.42M
Short Ratio 6.78
Short % of Float n/a
Beta 0.90
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 6.38
Revenue n/a
Operating Income -27.86M
Net Income -27.69M
Free Cash Flow -31.38M
Net Cash 27.31M
Net Cash / Share 0.87
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -85.98%
ROE -288.40%
ROIC 1,609.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 0
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

$22.50*
(312.09% upside)
Low
20.0
Current: $5.46
High
25.0
Target: 22.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue----------
Operating Income-23.00-14.06-5.00-5.08-8.54-7.42-5.04-3.52-3.89-2.59
Net Income-23.25-13.95-4.95-4.98-8.49-9.25-4.90-3.43-3.92-2.42
Shares Outstanding21.9120.0018.7818.6618.4113.6610.749.178.015.94
Earnings Per Share-1.06-0.70-0.26-0.27-0.46-0.68-0.46-0.30-0.45-0.45
Operating Cash Flow-11.25-12.39-2.36-5.86-7.41-4.49-4.05-2.94-2.22-2.07
Capital Expenditures-0.47-0.37-0.18-0.10-0.05-0.16-0.11-0.09-0.05-0.01
Free Cash Flow-11.72-12.76-2.54-5.96-7.45-4.65-4.16-3.03-2.27-2.07
Cash & Equivalents0.577.067.769.9915.968.543.504.091.920.09
Total Debt2.37--------0.14
Net Cash / Debt-1.807.067.769.9915.968.543.504.091.92-0.04
Assets6.5311.2311.4210.7717.089.914.735.142.741.09
Liabilities18.766.215.540.862.953.241.991.161.261.55
Book Value-12.225.025.889.9014.136.682.743.981.49-0.46
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Brainstorm Cell Therapeutics Inc.
Country United States
Employees 44
CEO Chaim Lebovits

Stock Information

Ticker Symbol BCLI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BCLI

Description

Brainstorm Cell Therapeutics, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in Phase II for the treatment of multiple sclerosis, and preclinical trial for Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company has a partnership with Catalent for the manufacture of NurOwn, an autologous cellular therapy. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.